Marinomed Biotech AG (STU:93Z) Tariff Resilience Score: 0/10 (As of Jul. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:93Z Marinomed Biotech AG STU:93Z
47 GF Score
Price €8.05
GF Value €17.47
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Marinomed Biotech AG Tariff Resilience Score?

Marinomed Biotech AG has the Tariff Resilience Score of 0, which implies that the company might have .

Marinomed Biotech AG has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Marinomed Biotech AG might have .

Marinomed Biotech AG  (STU:93Z) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Marinomed Biotech AG Tariff Resilience Score Related Terms

STU:93Z
47GF Score
Marinomed Biotech AG STU:93Z
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Marinomed Biotech AG (STU:93Z) Overvalued in 2026?

Based on GuruFocus' analysis, Marinomed Biotech AG stock appears to be undervalued. The current stock price of €8.05 is trading 53.9% below its estimated GF Value™ of €17.47. GuruFocus considers Marinomed Biotech AG to be Possible Value Trap.

Key valuation signals for STU:93Z:

  • Tariff Resilience Score: 0
  • GF Value™: €17.47 vs. price of €8.05 (53.9% below fair value)
  • GF Score™: 47/100 with 7 warning signs

No single metric tells the full story. See the STU:93Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Marinomed Biotech AG Business Description

Other Exchanges 93Z:GermanyMARI:Austria
Address Hovengasse 25, Korneuburg, AUT, 2100
Marinomed Biotech AG is a biopharmaceutical company focusing on the development of products in the field of respiratory and ophthalmological diseases. The company develops products for cough, cold, influenza, allergic rhinitis, and ophthalmic diseases. Its product offerings include virus-blocking nasal sprays, virus-blocking decongestant nasal sprays, virus-blocking lozenges, and virus-blocking throat sprays. The company has two reportable segments which are Virology, Immunology, and other, the majority of revenue generated from the virology segment.
47GF Score

Get the complete analysis for STU:93Z

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.05
Price
€17.47
GF Value